

Pharmaburst™ 500

Orally Disintegrating Tablet Platform

Pharmaburst was the first orally disintegrating tablet (ODT) platform on the market. Pharmaburst 500 is the current standard for its performance and versatility. It is an ideal choice among formulators because it addresses development challenges and creates premium products. It is a blend meeting globally accepted compendia and is used in over 60 commercialized products worldwide.

Pharmaburst 500 can simplify your formulation and manufacturing process while streamlining your path to market:

- Improve patient compliance
- Provide rapid disintegration
- Create robust tablets
- Improve drug loading capability



Patient Compliance

Pharmaburst 500 has excellent mouthfeel qualities that help improve patient compliance- making your drug product more successful. It has an optimum blend of polyols that deliver a smooth, creamy texture with a pleasant cooling sensation. Pharmaburst also has a neutral background flavor, accommodating any desired flavor profile for consumer satisfaction.


Rapid Disintegration

Fast disintegration time of 30 seconds or less is crucial for patient compliance with an ODT. An ODT that fails to perform as expected might require water for administration or chewing to facilitate swallowing- resulting in an unsatisfactory patient experience and increased risk of noncompliance.

Robust Tablets

Due to the compactable nature of Pharmaburst 500, robust tablets can be made by direct compression employing relatively low forces. Manufacturing durable tablets at lower compression forces is easier on equipment. It also reduces the stress applied to multiparticulates such as taste masked actives, a common component of ODT formulations, thereby ensuring that the integrity of the coat is maintained.

Figure 1: Tablet Disintegration Time Versus Hardness of Several Commercially Available Orally Disintegrating Platform Products





Globe Pharma 8 Station Instrumented Press, 25 RPM, 0.4375" FFBE Punches
 Tablet Weight: 400mg, mg stearate: 2.5%, Pre-compression: 0.0kN

Better Drug Loading Capability

The compaction behavior of Pharmaburst 500 contributes to its ability to carry high drug loads. The co-processed granules fracture around the drug particles during compression and fill void spaces. This characteristic allows Pharmaburst 500 to create durable and fast disintegration tablets without increasing tablet size.

Figures 2 and 3: Dilution Capacity of Pharmaburst 500 to Several Commercially available Orally Disintegrating Platform Products



Ease of Manufacturing

Pharmaburst 500 is designed to be a completely optimized platform that requires little formulation development. Orally disintegrating tablets formulated with Pharmaburst are also easy to manufacture using standard direct compression equipment and processes. The active(s) are simply blended with Pharmaburst, flavors, sweeteners, and colors. The lubricant is added in the final step and blended for the prescribed amount of time.

Value of Pharmaburst 500

Pharmaburst 500 produces fast disintegrating tablets that are hard enough to withstand the mechanics of production, storage, transportation, and being pushed out of a blister pack, yet will disintegrate rapidly so the patient can swallow their medication comfortably.

 SPI Pharma

 salesinfo@spipharma.com

 www.spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.

Order# SPI-DDL-PBR-6000-07201900

04-2026 | All rights reserved

© 2026 SPI Pharma